Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $375 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'